Trial Profile
A feasible study of datsatinib for Ph ALL in maintenance use at post allogeneic stem cell transplantation (KSGCT1101/DASALL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 20 Dec 2016
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Acronyms DASALL
- 18 Jun 2011 New trial record